DeepX Health is pleased to announce that daughter-company ScreenCancer has been awarded support from Innovation Norway for its Diagnostic Triage Algorithm-project. The project’s ambition is to streamline ScreenCancer’s teledermatology service for skin cancer in pharmacies by triaging skin lesions using a skin cancer algorithm in order to reduce time spent by dermatologists upon analysis and to reduce human error. The algorithm to be used is a new specification of Balter Medical's DermoSight algorithm. This project therefore demonstrates the synergies within DeepX Health.
We are very grateful for the support given to us, and proud to share the acknowledgement of our work. We are excited to discover the effects of the project, and will provide an update once the results are clear!
DeepX Health’s DermoSight featured on BBCRead more
DeepX Health’s DermoSight at NHS event on 12 JulyRead more
DeepX Diagnostics Inc.'s DermoSight Receives FDA Clearance for Teledermatology Screening of Suspect Skin Cancer LesionsRead more
DeepX Health’s Skin Cancer Teledermoscopy Services Now in JerseyRead more
New Board Advisor to DeepX HealthRead more
New Head of Product at DeepX HealthRead more
DeepX Health selected to present at Nordic Life Science DaysRead more
Pharmacy Screening Demonstrates Great Efficiency and Potential for Cost ReductionsRead more
Primary Care Setting Pilot Launched with NHSRead more
DeepX Health to Present at the 8th World Congress of Teledermatology, Imaging and Artificial Intelligence for Skin DiseasesRead more
DeepX Health to participate at the 7th Annual Dermatology Summit in San FranciscoRead more
DeepX Health to present at Digital Health World Congress in LondonRead more
DeepX Health participate in the DxPx ConferenceRead more
ScreenCancer approved for first round of Horizon 2020 programmeRead more